中國再生醫學：2022年第一季季度報告.pdf

1、FIRST QUARTERLY REPORT2022第一季季度報告INTERNATIONAL LIMITED中國再生醫學國際有限公司於開曼群島註冊成立之有限公司Incorporated in the Cayman Islands with limited liabilityStock Code 股份代號：8158CHINAREGENERATIVEMEDICINE12022 第一季季度報告 中國再生醫學國際有限公司CHARACTERISTICS OF GEM(“GEM”)OF THE STOCK EXCHANGE OF HONG KONG LIMITED(THE“STOCK EXCHANGE”)

2、GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange.Prospective investors should be aware of the potential risks of investing in such companies and should make th

3、e decision to invest only after due and careful consideration.Given that the companies listed on GEM are generally small and mid-sized companies,there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance i

4、s given that there will be a liquid market in the securities traded on GEM.Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever

5、for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.This report,for which the directors(the“Directors”)of China Regenerative Medicine International Limited(the“Company”)collectively and individually accept full responsibility,includes particul

6、ars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange(the“GEM Listing Rules”)for the purpose of giving information with regard to the Company and its subsidiaries(collectively the“Group”).The Directors,having made all reasonable enquiries,confirm tha